Lilly, AlzeCure ink Alzheimer’s drug deal (LLY:NYSE)
· seekingalpha.com
Eli Lilly (LLY) stock is in focus as Swedish biotech AlzeCure partners with the company to develop an Alzheimer’s therapy in a deal worth more than $1B. Read more here.
Swedish biotech AlzeCure Pharma announced on Tuesday a collaboration and a licensing agreement with Eli Lilly (LLY) to develop an Alzheimer’s therapy as part ...